A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care

N/ACompletedNCT02049099

Swedish Orphan Biovitrum1,658 enrolled

Overview

To describe the current treatment practice during 12 months for previously treated patients diagnosed with haemophilia A or haemophilia B.

The study population consists of patients with a diagnosis of ICD10: haemophilia A D66.9 or haemophilia B D67.9.

Study Type

OBSERVATIONAL

Enrollment

1,658

Conditions

Haemophilia A Haemophilia B

Eligibility

Sex: MALEMin age: 2 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male patients with severe or moderate haemophilia A or haemophilia B. * Treatment with Factor VIII/Factor IX products initiated at least 24 months before inclusion in the study. * Informed consent is obtained from the patient or patient's legal representative (as applicable according to legal regulation). Exclusion Criteria: * Confirmed positive inhibitor test detected in the past 24 months.

Locations (12)

Swedish Orphan Biovitrum Investigational Site

Brussels, Belgium

Swedish Orphan Biovitrum Investigational Site

Montpellier, France

Swedish Orphan Biovitrum Investigational Site

Nantes, France

Outcomes

Primary Outcomes

Total dose (IU) issued of Factor VIII during a 12 month period

Time frame: - 12 month to Day 0

Total dose (IU) issued of Factor IX during a 12 month period

Time frame: - 12 month to Day 0

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.